Miso Kim

Miso Kim

Auto-generated profile, based on publicly available information

Miso Kim

Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
RKRyul Kim
Ryul Kim
BKBhumsuk Keam
Bhumsuk Keam
SKSehui Kim
Sehui Kim
MKMiso Kim
Miso Kim
SKSe Hyun Kim
Se Hyun Kim
DHDae Seog Heo
Dae Seog Heo
We aimed to compare intra- and extracranial responses to immune checkpoint inhibitors (ICIs) in lung cancer with brain metastases (BM), and to explore tumor microenvironments of the brain and lungs focusing on the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway. Two cohorts of lung cancer patients with BM were analyzed. Cohort 1 included 18 patients treated with nivolumab or pembrolizumab, and intra- and extracranial responses were assessed. Cohort 2 comprised 20 patients who underwent both primary lung surgery and brain metastasectomy. Specimens from cohort 2 were subjected to immunohistochemical analysis for the following markers: CD3, CD4, CD8, FOXP3, and PD-1 on tumor infiltrating lymphocytes (TIL) and PD-L1 on tumor cells. Seven patients (38.9%) in cohort 1 showed progressive disease in both primary and intracranial lesions. Although the other 11 patients exhibited a partial response or stable disease in the primary lesion, eight showed a progression in BM. Interestingly, PD-1+ TILs were significantly decreased in BM (P = 0.034). For fifteen patients with adenocarcinoma, more distinctive patterns were observed in CD3+ (P = 0.078), CD8+ (P = 0.055), FOXP3+ (P = 0.016), and PD-1+ (P = 0.016) TILs. There may be discordant responses to an ICI of lung cancer between primary lung lesion and BM based on discrepancies in the tumor microenvironment. The diminished infiltration of PD-1+ TILs in tumor tissue within the brain may be one of the major factors that hinder the response to anti–PD-1 antibody in BM.


1 March 2020 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
CPChanghee Park
Changhee Park
MKMiso Kim
Miso Kim
MKMin Jung Kim
Min Jung Kim
HKHyeongmin Kim
Hyeongmin Kim
COChan-Young Ock
Chan-Young Ock
DHDae Seog Heo
Dae Seog Heo
Molecular profiling with next-generation sequencing (NGS) has been applied in multiple solid cancers to discover potential therapeutic targets. Here, we describe the results of a clinical NGS panel in patients with advanced melanoma. Thirty-six tumor tissues from patients with BRAF wild-type melanoma at Seoul National University Hospital (SNUH; Seoul, Republic of Korea) were collected and deep-sequenced using the SNUH FIRST-Cancer NGS panel to assess single-nucleotide variants, small insertions/deletions, copy number variations, and structural variations to estimate tumor mutation burden (TMB). We discovered 106 oncogenic alterations and most of the patients (n = 33, 92%) harbored at least one oncogenic alteration, including 2 patients who were initially diagnosed as BRAF V600E–negative but were later confirmed to be positive. Altogether, 36 samples were classified into RAS/BRAF/NF1–mutant (n = 14, 39%) or triple wild-type (n = 22, 61%) melanoma subtypes. The estimated median TMB was 8.2 mutations per Mb, ranging from 0 to 146.67 mutations per Mb. Of the 36 patients, 25 (70%) had actionable alterations with currently developed drugs, and 7 (19.4%) were enrolled in clinical trials with an RAF inhibitor, multiple receptor tyrosine kinase inhibitor, and anti-programmed cell death-1 (PD-1) antibody. TMB tended to associate with progression-free survival (PFS) of treatment with anti-PD-1/PDL-1 antibody (HR, 0.96; 95% confidence interval, 0.92–1.00; P = 0.07). High-TMB (≥13) group was associated with longer PFS than the low-TMB group (median 34.0 vs. 11.0 weeks, P = 0.04). Overall, the clinical use of a NGS panel in patients with advanced melanoma shows association with clinical outcomes and several therapeutic strategies.

26 September 2024 in Prostate International
Verified
Journal Article
Open access
HYHyeong Dong Yuk
Hyeong Dong Yuk
MKMiso Kim
Miso Kim
BKBhumsuk Keam
Bhumsuk Keam
JKJa Hyun Ku
Ja Hyun Ku
CKCheol Kwak
Cheol Kwak
CJChang Wook Jeong
Chang Wook Jeong
Background: To compare the efficacy and toxicity of docetaxel treatment regimens in metastatic castration-resistant prostate cancer (mCRPC). Methods: We retrospectively analyzed 162 patients diagnosed with mCRPC who underwent docetaxel chemotherapy between 2009 and 2020. The patients were divided into three groups according to the dosage and interval of docetaxel (DCT) chemotherapy regimen: 30 mL/m(2) weekly, 50 mL/m(2) biweekly (every 2 weeks), and 75 mL/m(2) triweekly (every 3 weeks). Results: There were no significant differences in the prostate-specific antigen (PSA) response rates (P = 0.709). The median time to progression was 3.0 [interquartile range (IQR 2.0-5.3)] months, 5.0 (IQR 2.0-13.0) months, and 5.0 (IQR 3.0-12.0) months in the weekly, biweekly, and triweekly groups, respectively (P = 0.062). The median overall survival (OS) was 12.5 (IQR 6.0-14.0) months, 18.8 (IQR 5.5-23.5) months, and 22.9 (IQR 11.0-33.0) months in the weekly, biweekly, and triweekly groups, respectively (P < 0.001). There were no differences in all toxicity and Grade 3 or higher toxicity. In Cox multivariate regression analysis, the Eastern Cooperative Oncology Group performance status (ECOG-PS), response to chemotherapy, and chemotherapy cycle also affected the PFS. Age, ECOG-PS, and chemotherapy cycle affected the OS. Conclusions: The various options for optimal chemotherapy are indicated depending on the patient's conditions during the diagnosis of mCRPC. Treatment with DCT at 2-week or even 1-week intervals appears to be well tolerated in men diagnosed with mCRPC and represents a useful option when the conventional triweekly regimen is not tolerated due to poor patient condition.

23 September 2019 in Research Square
Verified
Preprint
Open access
JPJoohwan Park
Joohwan Park
MKMiso Kim
Miso Kim
TKTae-Min Kim
Tae-Min Kim
BKBhumsuk Keam
Bhumsuk Keam
DKDong-Wan Kim
Dong-Wan Kim
DHDae Seog Heo
Dae Seog Heo
Systemic inflammatory response index such as neutrophil-to-lymphocyte ratio (NLR) or platelet-to-lymphocyte ratio (PLR) has been investigated as prognostic indicators in various tumors including diffuse large B-cell and peripheral T-cell lymphomas. The aim of this study is to evaluate the prognostic values of the pretreatment NLR and PLR in patients with advanced, extranodal NK/T-cell lymphoma, nasal type (NTCL). Sixty patients with newly diagnosed, stage III/IV NTCL between January 2000 and August 2015 were evaluated retrospectively. Correlations of pre-NLR and –PLR with other clinical factors were investigated. Kaplan-Meier plot was used to analyze survivals according to pre-NLR and -PLR levels. The prognostic effects of variables were investigated using a Cox proportional regression model. Based on the optimized cut-off levels, patients were classified into two different groups. After a median follow up of 15 months, the median overall survival (OS) in the low and high pre-NLR groups was 33.4 and 6.6 months, respectively. In multivariate analysis, high pre-NLR was significantly associated with reduced OS (hazard ratio [HR] 3.59, 95% CI 1.77-7.26; p < .001). On the contrary, the median OS in the low and high pre-PLR was 6.2 and 22.3 months, respectively. Multivariate analysis revealed that low pre-PLR was in a significant correlation with the worse OS (HR 3.78, 95% CI 1.79-7.95; p < .001). The high pre-NLR and low pre-PLR are independent poor prognostic factors for reduced survivals of patients with advanced NTCL, and might provide additional prognostic powers to identify high-risk, advanced NTCL patients.